+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bio Decontamination Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5616798
The bio-decontamination market is projected to register a CAGR of 6.2% during the forecast period (2022 - 2027).

As the impact of the COVID-19 outbreak widens and the number of patients being admitted to hospitals grows, medical professionals and hospital administrators were looking for emergency alternatives that provide more beds for patients during the crisis by leveraging empty facilities, re-purposing space within an existing hospital, or building temporary structures to serve as hospitals, many options are being implemented to best serve the public as the Coronavirus spreads.​ Hospital-acquired COVID-19 represents a serious public health issue, which is a problem that creates reluctance of patients to seek hospital treatment for fear of becoming infected. According to the report “Hospital-Acquired SARS-Cov-2 Infections in Patients: Inevitable Conditions or Medical Malpractice?” published in January 2021, the SARS-CoV-2 hospital-acquired infection rate is 12-15% globally.​ According to the study “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China,” published in February 2020, Hospital-associated transmission was suspected in 12.3% of hospitalized patients initially admitted for other health issues. Thus, with the high incidence of hospital-acquired infections during the Coronavirus times, healthcare facilities are taking more care of hygiene in the healthcare facilities, thus driving the growth of the market.​ Hence, due to the pandemic, the necessity to use sterilization has increased, and the market is expected to grow.

Prevention of hospital-acquired infections is a critical aspect of clinical management of COVID-19, as hospital-acquired infections have been a common feature of novel coronavirus outbreaks. According to the study “Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave,” published in August 2021, 11.3% of patients with COVID-19 in 314 United kingdom hospitals became infected after hospital admission. This rate increased to 15.8% in May 2020. Thus, the outbreak has impacted the healthcare facilities in managing hospital-acquired infections.​ Hospital-acquired infections (HAI) are nosocomially acquired infections that are not present or incubating at the time of admission to a hospital. These infections are contracted because of an infection or toxin in hospitals.​ These infections include catheter-associated urinary tract infections, central line-associated bloodstream infections, surgical site infections, ventilator-associated pneumonia, hospital-acquired pneumonia, and Clostridium difficile infections.​ The risk factors for HAI include immunosuppression, older age, length of stay in the hospital, multiple underlying comorbidities, frequent visits to healthcare facilities, mechanical ventilatory support, recent invasive procedures, indwelling devices, and stay in an intensive care unit (ICU).​ According to World Ageing Report 2019, there were 703 million persons aged 65 years or over in the world in 2019, and this number of older persons is projected to double to 1.5 billion in 2050. The elderly population is at high risk of contracting infectious diseases as they frequently visit hospitals and have poor immune systems. Thus, the growing geriatric population is expected to boost the incidence of HAI as the aging population would have a weak immune system, increasing their chances of getting infected, thus driving the market.​ Persons with multiple underlying comorbidities such as cardiovascular diseases, blood diseases, diabetes, cancer, etc., are more prone to HAIs. According to World Health Organization, in 2019, the global prevalence of anemia in women of reproductive age was 29.9%, in non-pregnant women of reproductive age was 29.6%, in pregnant women was 36.5%, and in children aged between 59 months, it was 39.8%. These people report frequent hospital visits and are at higher risk of infections, thus driving the market. Thus, owing to the abovementioned factors, the studied market is expected to grow significantly over the forecast period.​

However, limitations in reallocating resources and adjusting budgets in health care may hamper the usefulness of economic evaluation for decision-making as limited resources would hinder the adoption rate of bio-decontamination devices and services. Thus, budgetary constraints in healthcare facilities are expected to hinder the market growth.

Key Market Trends

Hospitals & Healthcare Facilities are Expected to Hold a Significant Market Share Over the Forecast Period

Factors such as increasing infections in hospitals and research studies are expected to drive the growth of the market in the upcoming future. According to the report “Mortality attributable to hospital-acquired infections with multidrug-resistant bacteria in a large group of German hospitals,” published in February 2020, 1,136 suffered a hospital-acquired multidrug-resistant organism (MDRO) infection, out of which 215 patients died. Thus, the high incidence and mortality rates associated with hospital-acquired infections are expected to boost the studied market growth over the forecast period.​ According to the report “Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014-2018,” published in May 2020, there was a 59% increase in methicillin-resistant S. aureus bloodstream infections and a 143% increase in vancomycin-resistant Enterococci bloodstream infections. These infections are types of hospital-acquired infections. Thus, high incidences of such infections drive the demand for proper maintenance of hospital hygiene, thus driving the market.​ According to the report “Modelling the annual National Health Service (NHS) costs and outcomes attributable to healthcare-associated infections in England,” published in 2020, there were an estimated 653,000 hospital-acquired infections among the 13.8 million adult inpatients in National Health Service general and teaching hospitals in England, of which 22,800 patients died as a result of their infection. Thus, the high incidence of these infections and the high mortality rate associated with them are expected to drive market growth over the forecast period.​ Hence, the studied market is expected to grow due to the factors mentioned above over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

The robust growth of the healthcare sector in North America, increasing incidences of hospital-acquired infections in the region, the growing geriatric population, greater government initiatives, and investments toward hygiene in healthcare facilities are expected to boost the market growth. ​According to the “2020 HAI Progress Report Executive Summary” report published by the Centers for Disease Control and Prevention, every day, approximately one in 31 United States patients contracts at least one infection in association with hospital care, highlighting the need for improvements in patient care practices in the country’s healthcare facilities. Thus, the incidence of hospital-acquired infections in the country drives the need for proper hygiene maintenance, including timely changing of hospital curtains, thus driving the market.​ According to data published by Canadian Institute for Health Information, in 2019-2020, there were over 3 million acute inpatient hospitalizations in Canada. The country's most common reason for hospitalization was giving birth, with an average acute length of stay of 2.2 days, whereas for bronchitis, it is 7.1 days. Since high hospital admission and long hospital stays are expected to increase the incidence of hospital-acquired infections as longer stay increases the chances of getting infections, thus driving the market growth. According to the “Guidelines for Environmental Infection Control in Health-Care Facilities” by the Centers for Disease Control and Prevention updated in July 2019, it is important to monitor and document daily the negative airflow in airborne infection isolation rooms (AII) and positive airflow in protective environment rooms (PE), especially when patients are in these rooms. After that, the facility must perform assays at least once a month using standard quantitative methods for endotoxin in water used to reprocess hemodialyzers and for heterotrophic, mesophilic bacteria in water used to prepare dialysate and for hemodialyzer reprocessing. Such guidelines issued by the government will boost the hygiene in healthcare facilities, driving the market.​

Hence, the studied market is expected to grow due to the aforementioned factors over the forecast period.

Competitive Landscape

The market is partially fragmented and consists of several major players. Some of the companies which are currently dominating the market are STERIS plc, Ecolab, TOMI Environmental Solutions Inc., JCE Biotechnology, and Zhejiang Tailin Bioengineering Co., Ltd. among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Hospital-Acquired Infections
4.2.2 Increasing Number of Surgical Procedures
4.2.3 Increasing Outsourcing of Biodecontamination Services
4.3 Market Restraints
4.3.1 Budgetary Constraints in Healthcare Facilities
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product & Service
5.1.1 Equipment
5.1.2 Services
5.1.3 Consumables
5.2 By Agent Type
5.2.1 Hydrogen Peroxide
5.2.2 Chlorine Dioxide
5.2.3 Peracetic Acid
5.2.4 Nitrogen Dioxide
5.3 By End User
5.3.1 Pharmaceutical & Medical Device Manufacturing Companies
5.3.2 Life Sciences & Biotechnology Research Organizations
5.3.3 Hospitals & Healthcare Facilities
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Rest of World
6.1 Company Profiles
6.1.1 Amira S.r.l.
6.1.2 Chemamde
6.1.3 ClorDiSys Solutions Inc
6.1.4 Ecolab
6.1.5 Fedegari Autoclavi S.p.A.
6.1.6 Howorth Air Technology Limited
6.1.7 JCE Biotechnology
6.1.8 Noxilizer, Inc.
6.1.9 STERIS plc
6.1.10 TOMI Environmental Solutions Inc.
6.1.11 Zhejiang Tailin Bioengineering Co., Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amira S.r.l.
  • Chemamde
  • ClorDiSys Solutions Inc
  • Ecolab
  • Fedegari Autoclavi S.p.A.
  • Howorth Air Technology Limited
  • JCE Biotechnology
  • Noxilizer, Inc.
  • STERIS plc
  • TOMI Environmental Solutions Inc.
  • Zhejiang Tailin Bioengineering Co., Ltd.